Chapter 3 - The Company Elena Thought Had Been Stolen Was Already Failing
Arclight’s independent board suspended the Aurelis license the following morning.
Temporarily.
It did not return Elena to the CEO chair.
That surprised Cassandra.
It also disappointed Elena more than she admitted.
Margaret Sloan was blunt.
“You are recovering from surgery.”
“That isn’t disqualification.”
“No.”
Margaret pushed the governance report across the table.
“But Arclight also ran out of money while you were CEO.”
Elena went quiet.
The financial problems were real.
Arclight had raised $64 million over thirteen years.
Their core platform used engineered lipid carriers to deliver highly targeted therapies.
The science was promising.
Commercialization remained expensive.
Manufacturing yields had fallen.
A partner terminated a development agreement.
Elena repeatedly delayed layoffs because she believed another financing round would close.
It didn’t.
Julian had warned her.
Cassandra had too.
Elena remembered telling both:
“If we cut the development team now, we destroy the thing investors are funding.”
Maybe.
Maybe she had also been unable to admit the company she founded needed to become smaller.
Margaret continued:
“Your removal as CEO may have been opportunistic.”
Elena waited.
“That does not mean every concern used to justify it was fabricated.”
Elena hated the sentence.
She needed it.
The independent committee appointed an interim CEO from outside the company.
No Cassandra.
No Elena.
Julian remained CFO only long enough to assist the review.
Adrian’s laboratory records underwent forensic validation.
No one simply accepted them because Cassandra looked guilty.
The investigators compared:
instrument timestamps,
server backups,
laboratory notebooks,
manufacturing batches,
email chains,
and the altered summary Cassandra had presented to the board.
Adrian had not falsified the underlying data.
He had refused to sign a stability projection extending beyond what the experiments supported.
Cassandra wanted a longer performance window because investors demanded it.
Adrian said no.
Three weeks later he was accused of “data integrity concerns.”
Elena asked him:
“Why didn’t you tell me?”
They were meeting in Arclight’s temporary board offices.
Adrian looked uncomfortable.
“I tried.”
“When?”
He showed her three emails.
All sent while Elena was traveling for investor meetings.
Julian was copied.
Cassandra was copied.
Elena was not.
She stared at the recipient list.
“Why am I not here?”
Adrian looked at Julian.
Julian answered:
“Because I told him I’d handle it.”
Elena felt cold.
Adrian had raised a scientific governance concern.
Julian intercepted it as CFO.
“Why?”
“Because you were already dealing with the surgery diagnosis.”
Elena laughed once.
“There it is again.”
Protection.
Her illness had become the most useful excuse in the company.
Julian continued:
“I thought Cassandra and Adrian could resolve it.”
“Did they?”
“Obviously not.”
Adrian’s removal damaged Arclight’s credibility.
Cassandra then used the credibility problem to argue the company needed a new leadership structure.
Julian supported her.
Elena asked:
“Were you sleeping with her then?”
Julian’s silence answered.
Cassandra looked away.
Elena felt something almost detach inside her.
“How long?”
Julian finally said:
“Five months.”
The affair began before Elena’s surgery.
Before the emergency board meeting.
Before the Aurelis transaction.
Cassandra had not merely taken advantage of Elena’s vulnerability after the fact.
She and Julian had already created a secret alliance.
Then the forensic accountants found the first evidence that alliance was not financially equal.
Cassandra owned forty-one percent of Aurelis.
Julian owned nothing.
Instead, he held a side agreement.
If Aurelis completed a major financing, Julian would receive a substantial cash bonus and an option package from a different company.
Elena had never heard of that company.
May you like
Northstar Bio Holdings.
Cassandra had not either.
